Breaking News

Deutsche Telekom Said to Deem Iliad's Offer as Non-Competitive
Tweet TWEET

Healthcare Companies Report Financial Results, Scheduled Presentations, Marketing Clearance and Recognitions - Research Report

   Healthcare Companies Report Financial Results, Scheduled Presentations,
    Marketing Clearance and Recognitions - Research Report on Air Methods,
                NeuroMetrix, Quintiles, Auxilium, and Cynosure

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, November 12, 2013

NEW YORK, November 12, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Air
Methods Corp. (NASDAQ: AIRM), NeuroMetrix Inc. (NASDAQ: NURO), Quintiles
Transnational Holdings Inc. (NYSE: Q), Auxilium Pharmaceuticals Inc. (NASDAQ:
AUXL), and Cynosure, Inc. (NASDAQ: CYNO). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Air Methods Corp. Research Report 

On November 7, 2013, Air Methods Corp. (Air Methods) released its Q3 2013
financial results. Total revenues were up by 14.1% YoY to $252.4 million
during the quarter. Net income was $35.6 million or $0.91 per diluted share in
Q3 2013, compared to $27.8 million or $0.71 per diluted share in Q3 2012.
Commenting on the results, Aaron Todd, CEO of Air Methods, stated, "Our third
quarter reflects a return to growth in earnings fueled by strong growth in net
revenue per patient transport and more moderate maintenance expenditures as
anticipated. Our growth in net revenue per transport reflects more stable
year-over-year payer mix and has been realized while reducing our days' sales
outstanding, which decreased from 108 days as of September 30, 2012 and 99
days as of June 30, 2013, to 92 days as of September 30, 2013 based on 90-day
annualized net revenue. We are also very pleased that our investment in
Sundance and the tourism sector continues to generate accretive financial
results, in line with our initial expectations." The Full Research Report on
Air Methods Corp. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/ff38_AIRM]

--

NeuroMetrix Inc. Research Report 

On November 7, 2013, NeuroMetrix Inc. (NeuroMetrix) announced that Shai N.
Gozani, M.D., Ph. D., President and CEO of the Company, is scheduled to
present at the Canaccord Genuity Medical Technology & Diagnostics Forum, at
the Westin Grand Central, New York, on November 14, 2013 at 8:00 am EDT.
NeuroMetrix informed that in his presentation, Dr. Gozani will provide an
update on the Company's business activities with emphasis on its SENSUS™ pain
management system for relief of chronic intractable pain, including pain
associated with diabetic neuropathy. The Full Research Report on NeuroMetrix
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/b5b2_NURO]

--

Quintiles Transnational Holdings Inc. Research Report 

On November 6, 2013, Quintiles Transnational Holdings Inc. (Quintiles)
announced that the Healthcare Businesswomen's Association (HBA) has honored
the Company's Women Inspired Network (WIN) with the 2013 HBA ACE Award.
According to the Company, it will receive the ACE Award at the 2013 HBA
Leadership Conference, to be held in Boston, Massachusetts, on November 14,
2013. Commenting on the achievement, Tom Pike, CEO of the Company, stated,
"Winning the 2013 HBA ACE Award validates Quintiles' significant efforts to
foster the development of women leaders throughout our organization and the
industry. WIN is a very important part of the fabric of our organization and
one of the great catalysts we have internally for leadership development.
Women comprise about 65% of Quintiles' population and we promote the idea that
women innovate, achieve business goals and advance Quintiles' industry
leadership in every job throughout the company." The Full Research Report on
Quintiles Transnational Holdings Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

[http://www.analystscorner.com/r/full_research_report/9f5c_Q]

--

Auxilium Pharmaceuticals Inc. Research Report 

On November 6, 2013, Auxilium Pharmaceuticals Inc. (Auxilium) released its Q3
2013 financial results. On a GAAP basis, net revenues (including Actient
revenues from its acquisition date, April 26, 2013) of the Company were up by
52.3% YoY to $108.1 million during the quarter. GAAP net loss in Q3 2013 was
$28.9 million or $0.59 per diluted share, compared to GAAP net loss of $10.5
million or $0.21 per diluted share in Q3 3012. Commenting on the results,
Adrian Adams, CEO and President of Auxilium, stated, "We are pleased with the
overall momentum of the business and are delighted to deliver what we consider
to be a strong third quarter of record revenues in addition to significant
non-GAAP earnings per share growth." The Full Research Report on Auxilium
Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/86a4_AUXL]

--

Cynosure, Inc. Research Report

On November 6, 2013, Cynosure, Inc. (Cynosure) announced that Australia's
Therapeutic Goods Administration has granted marketing clearance for the
PicoSure™ Picosecond Laser (PicoSure). According to the Company, PicoSure, the
world's first picosecond laser for the removal of tattoos and benign pigmented
lesions, was introduced in the US at the beginning of 2013 after receiving
clearance from the U.S. Food and Drug Administration. Commenting on the
release, Michael Davin, Cynosure's President and CEO stated, "PicoSure
continues to be enthusiastically received by physicians and consumers in North
America and Europe, and we are excited about the opportunity to market the
product to our customers and their patients in Australia, which is a new
direct sales territory for the Company." The Company informed that it has also
received approval from the China Food and Drug Administration to market
Smartlipo MPX™ LaserBodySculpting™ Workstation, the industry's leading
laser-assisted lipolysis system designed to disrupt fat cells and tighten
tissue through tissue coagulation. The Full Research Report on Cynosure, Inc.
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/6e59_CYNO]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)